Safety Study of GRNOPC1 in Spinal Cord Injury

General Information

Summary The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Description Not Provided
Clinical trials phase Phase 1
Start date (estimated) 2010-10-01
End date (estimated) 2013-07-31
Clinical feature
Label Spinal Cord Injury
Link http://purl.obolibrary.org/obo/NCIT_C50750
Description Traumatic damage of the spinal cord.

Administrative Information

NCT number NCT01217008
ICTRP weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01217008
Other study identifiers
Name CP35A007
Source weblink https://clinicaltrials.gov/ct2/show/record/NCT01217008
Regulatory body approval
Name Food and Drug Administration (FDA)
Country
United States
Public contact
Email MedicalInquiries@asteriasbio.com
Country
United States
Sponsors Asterias Biotherapeutics, Inc

Cell Line

Stem cell lines obtained from

Recruitment

Recruitment Status Completed
Estimated number of participants 5